// App-Quantinova.ai

PO0436 : Defining the Excess Risk of Adverse Kidney Outcomes in CKD Patients with Type 2 Diabetes in the DISCOVER-CKD Cohort

Researchers

Presenter

  • Abdul Sultan Alyshah

Principal Investigators

  • Nolan Stephen

  • Carrero JuanJesus

  • Jiang Zhuoxin

  • Kumar SupriyaR

  • Pecoits-Filho Roberto

  • James Glen

  • Garcia Sanchez Juan Jose

  • Carolyn LamSu ping

  • Chen Hungta (tony)

  • Kanda Eiichiro

  • Kashihara Naoki

  • Kosiborod Mikhail

  • Pollock CarolA

  • Wheeler DavidC

  • L Heerspink HiddoJan

Medical Centers

  • Astra Zeneca, Cambridge, United Kingdom

  • Karolinska Institutet, Karolinska Institute, Stockholm, Sweden

  • AstraZeneca Gaithersburg Maryland United States

  • Arbor Research Collaborative for Health, Ann Arbor, United States of America

  • National Cancer Centre Singapore, Singapore, Singapore

  • Kawasaki Ika Daigaku Kurashiki Okayama Japan

  • St Lukes Mid America Heart Institute Kansas City Kansas United States

  • Royal Northshore Hospital, St Leonards, New South Wales, Australia

  • Kings College London, London, United Kingdom

  • Rijksuniversiteit Groningen, Groningen, Netherlands

Locations

  • United Kingdom

  • Sweden

  • United States

  • Singapore

  • Japan

  • Australia

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • Microvascular complications of diabetes 1

  • Type 2 diabetes mellitus

  • Renal disease

  • Diabetes

Biomarkers

  • Creatinine

  • Human albumin

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Observational

  • Multinational

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved